TCGA-BH-A18F-01A-11R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 33
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- ADIPOGENESIS+0.390
- MITOTIC_SPINDLE+0.380
- UV_RESPONSE_DN+0.380
- G2M_CHECKPOINT+0.360
- MYOGENESIS+0.360
- ANGIOGENESIS+0.340
- E2F_TARGETS+0.340
- TNFA_SIGNALING_VIA_NFKB+0.330
- APICAL_JUNCTION+0.310
Top 10 suppressed
- UNFOLDED_PROTEIN_RESPONSE-0.150
- INTERFERON_ALPHA_RESPONSE-0.120
- SPERMATOGENESIS-0.110
- MTORC1_SIGNALING-0.070
- MYC_TARGETS_V1-0.070
- MYC_TARGETS_V2-0.050
- DNA_REPAIR-0.040
- NOTCH_SIGNALING-0.020
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.020
- PROTEIN_SECRETION+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_4733_T1_RNA | — | A | 0.837 |
| 2 | SRR33346953 | — | — | 0.829 |
| 3 | BSR_19_0096_S47 | — | A | 0.822 |
| 4 | MDT-AP-0205 | Med | Medulloblastoma | 0.809 |
| 5 | 718de66e-06d2-4c2c-8b2d-e40087c4340c | — | — | 0.804 |
| 6 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.781 |
| 7 | TCGA-92-7340-01A-21R-2045-07 | — | cohortSQ1 | 0.775 |
| 8 | MNG893 | — | — | 0.769 |
| 9 | TCGA-GM-A2DL-01A-11R-A18M-07 | — | C | 0.768 |
| 10 | SRR27320688 | — | — | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |